Ozempic, Novo Nordisk's diabetes drug, may see increased sales due to potential brain benefits.

Ozempic, Novo Nordisk's diabetes drug, could see a massive sales surge due to new research indicating potential brain benefits. As a GLP-1 drug, Ozempic has been successful in curbing appetite, but recent studies suggest it may also have positive effects on the brain. This could unlock a significant revenue opportunity for the healthcare company and increase the drug's value in the healthcare market.